Licence extension for Januvia

01 October 2009, 9:18am

Januvia (sitagliptin) is now licensed for first-line treatment of type II diabetes when metformin is contraindicated or not tolerated. The recommended dose is 100mg once daily.

View Januvia drug record

Further information: Merck

Email this

You must log in to make full use of all the site content and features.

New users can register here free for full site access.

Related Drug Categories

Oral and parenteral hypoglycaemics

Latest Licence Changes News

MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Browse drugs by therapeutic area

MIMS monthly print registration

NICE Guidance: IBS

MIMS Summary of
NICE guideline

NICE Guidance: Lipid Modification

MIMS Summary of
NICE guideline

Quick-reference table: antibiotics

Treatment regimens for common infections

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines